Prostate Cancer Clinical Trials (2026): 936 Recruiting Interventional Studies

Last updated: April 2, 2026

Current Clinical Trial Landscape

Recruiting Trials by Disease Stage

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

ADT + AR-pathway inhibitor ± docetaxel is standard. Trials explore intensification and PSMA-based approaches:

• Triplet therapy / intensification:
  • NCT06931340 - ADT + Apalutamide ± Docetaxel in metastatic prostate cancer (Phase 3)
  • NCT05983783 - Rezvilutamide + ADT + Docetaxel vs Rezvilutamide + ADT in mHSPC (Phase 3)
  • NCT07241416 - Rezvilutamide in mHSPC (Phase 3)
  • NCT06349825 - Cytoreductive prostatectomy + triple or dual systemic therapy (Phase 3)
• PSMA-directed in mHSPC:
  • NCT06496581 - PEACE6: SOC ± 177Lu-PSMA-617 in de novo mHSPC with poor PSA response (Phase 3)
• De-escalation:
  • NCT07260435 - Shorter treatment with ARPI in low-volume mHSPC (Phase 3)
• Suboptimal response:
  • NCT06592924 - Adding docetaxel to ARPI in mCSPC with suboptimal PSA response (Phase 3)

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

207 recruiting trials. The most active area of research:

• Bispecific T-cell engagers:
  • NCT06691984 - Xaluritamig (STEAP1×CD3) vs Cabazitaxel or second ARPI (Phase 3)
  • NCT07164443 - Pasritamig (PSMA×CD3) vs Placebo in late-line mCRPC (Phase 3)
  • NCT07225946 - Pasritamig + Docetaxel vs Docetaxel in mCRPC (Phase 3)
• Next-gen AR-targeted:
  • NCT06136650 - Opevesostat (CYP11A1 inhibitor, MK-5684) vs alternative NHA in mCRPC (Phase 3)
  • NCT07028853 - Mevrometostat (EZH2 inhibitor) + Enzalutamide in mCRPC (Phase 3)
  • NCT03851640 - HC-1119 (next-gen anti-androgen) in mCRPC (Phase 3)
• PSMA radioligand:
  • NCT06854277 - AAA817 (PSMA-targeted) + ARPI vs SOC in PSMA+ mCRPC (Phase 3)
• BRCA/HRR-mutated:
  • NCT06120491 - Saruparib (AZD5305) vs Placebo + NHA in mCSPC with BRCA/HRR (Phase 3)
• Platform / biomarker-driven:
  • NCT03903835 - ProBio: Biomarker-driven multi-arm platform trial in metastatic prostate cancer (Phase 3)
  • NCT06320067 - Platform trial testing treatments in mHSPC (Phase 3)

Biochemical Recurrence / Oligometastatic

• NCT04794777 - Salvage RT vs PSMA PET/CT-targeted treatment in relapsing prostate cancer (Phase 3)
• NCT05352178 - Metastasis-directed therapy for oligorecurrent prostate cancer (Phase 3)
• NCT04787744 - Standard systemic therapy ± PET-directed local therapy for oligometastatic prostate cancer (Phase 2/3)
• NCT04423211 - Apalutamide + PSMA PET-guided targeted radiation for BCR (Phase 3)
• NCT05939414 - 177Lu-vipivotide tetraxetan vs Observation in PSMA+ oligometastatic prostate cancer (Phase 3)
• NCT06276465 - Darolutamide ± radiation for CRPC with metastases on functional imaging (Phase 3)

Localized / Post-Surgery

• NCT05116475 - Darolutamide + ADT + radiation in newly diagnosed prostate cancer with limited metastases (Phase 3)
• NCT06274047 - PROSTATE-IQ: Personalized apalutamide treatment post-operative (Phase 3)
• NCT03678025 - Standard systemic therapy ± definitive treatment in metastatic prostate cancer (Phase 3)
• NCT05946213 - Shorter duration vs usual radiation in high-risk prostate cancer (Phase 3)

Novel Approaches

• Bispecific T-cell engagers: Xaluritamig (STEAP1×CD3) and pasritamig (PSMA×CD3) — first bispecifics reaching Phase 3 in prostate cancer, targeting mCRPC after AR therapy and chemotherapy
• PSMA radioligand therapy expansion: Moving from mCRPC to mHSPC (PEACE6) and oligometastatic settings
• AR degraders / novel AR targets: Opevesostat (CYP11A1), mevrometostat (EZH2), rezvilutamide — targeting AR signaling through new mechanisms
• PSMA PET-guided treatment: Multiple Phase 3 trials using PSMA PET to guide radiation, surgery, and systemic therapy decisions

Trial listings from ClinicalTrials.gov. Page summaries generated by AI and may contain errors. Always verify with your healthcare provider.

Frequently Asked Questions